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Abstract 
Samples and data of large prospective cohort (LPC) studies stored in biobanks represent an invaluable resource 
for health research. Efficient sharing and pooling of samples and data is a central pre-requisite for new advances 
in biomedical science. This requirement, however, is not compatible with the present scattered and traditional 
access governance structures, where legal and ethical frameworks often form an obstacle for effective sharing. 
Moreover, the EU General Data Protection Regulation (GDPR) is demanding increasingly rigorous 
administration from all those organisations processing personal data. The BBMRI-LPC project (Biobanking and 
Biomolecular Research Infrastructure ― Large Prospective Cohorts) assembled 21 LPCs from 10 countries and 
two EU-wide multinational cohort networks with a key objective to promote collaborative innovative 
transnational research proposed by external researchers on the broad field of common chronic diseases, and 
analyze the gaps and needs involved. BBMRI-LPC organized three scientific calls  to offer European 
investigators an opportunity to gain free of charge transnational access to research material available in the 
participating cohorts. A total of 11 high-quality research proposals involving multiple prospective cohorts were 
granted, and the access process in the individual projects carefully monitored. Divergent access governance 
structures, complex legal and ethical frameworks and heterogeneous procedures were identified as currently 
constituting substantial obstacles for sample and data transfer in Europe. To optimize the scientific value and use 
of these research resources, practical solutions for more streamlined access governance in collaborative projects 
are urgently needed. A number of infrastructure developments could be made to improve time-efficiency in 
access provision.
Keywords: biobanks; transnational access; cohort studies; GDPR; collaborative research 
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EEA, European economic area 
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Introduction
Prospective large population-based cohort studies (i.e. longitudinal studies on a collection of biological, clinical 
and other data from large numbers of individuals with shared characteristics) have a fundamental role in identifying 
etiological risk factors for common chronic diseases [1–4]. In contrast to other study designs (e.g. case-control 
studies), prospective studies are not affected by recall or other biases, as the risk factors are measured prior to the 
onset of the targeted disease outcomes [5]. A high number of large prospective cohort (LPC) studies have been 
carried out across Europe over the last decades. These cohorts constitute a mixture of ‘mature cohorts’ with an 
extensive follow-up of several decades, and ‘contemporary cohorts’ with more recent and often enriched exposure 
information. Some of these cohorts have recruited hundreds of thousands of study participants (e.g. UK Biobank 
and the EPIC cohort), representing major investments of public funding, as well as time and effort from study 
participants and researchers. With their clinical samples and extensive exposure information stored in biobanks 
(biorepositories accepting, processing, storing and distributing biospecimens and associated data for use in 
research and clinical care), the LPC studies represent an invaluable resource for health research [4, 6]. 
To enable analysis of diseases in a reliable manner, prospective cohorts need to be large enough to accrue 
sufficiently high numbers of incident disease cases during the follow-up. Consequently, studying rare or 
moderately common endpoints in a single prospective cohort is often challenging. In many cases, pooling 
resources across multiple cohorts from different countries is required to assemble sufficient sample size for 
answering important research questions. Consortium-based cohort studies are instrumental to study less common 
disease endpoints, highlighting the importance of collaborative cohort research in Europe. These multinational 
research projects, however, are often challenged by sample and data sharing difficulties due to limited resources 
and heterogeneous, country- and cohort-specific access procedures. 
A major logistical hurdle for effective transnational sharing is the absence of centralized and uniform access 
governance [7]. Multiple time-consuming processes specified in the national legislations and local rules have to 
be complied with, which may markedly increase the time needed before the actual research can commence. 
Heterogeneity in access procedures is not only observed across regions (e.g. the EU), but even between  different 
cohorts/biobanks within a single country [8]. Regrettably, the burden of current fragmentation falls on the scientist 
and the laboriousness of transnational access procedures tend to impede the actual science [9, 10]. 
While streamlining access governance systems is not a straightforward task, there are already a number of 
initiatives ongoing to rationalize and harmonize access policies and procedures across Europe. There is a growing 
international consensus on the need for improved access to optimize the long-term value of available sample and 
data collections and to exploit their full potential for health discovery and validation [7]. The pan-European 
BBMRI-ERIC (Biobanking and Biomolecular Resources Research Infrastructure - European Research 
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Infrastructure Consortium) may prove a promising platform for increased access harmonization, centralization and 
e-governance [11]. Another way to promote more harmonized and streamlined access solutions is an international 
Charter that outlines guiding principles for international sample and data sharing, accompanied by a general model 
for a Material and Data Transfer Agreement (MTA/DTA) [7]. 
In this paper, we report and discuss the specific bottlenecks identified in the transnational access process identified 
during the four-year (2013-2017) EU infrastructure project BBMRI-LPC. Furthermore, we provide a set of 
recommendations to improve the efficacy of access provision to the cohort research resources in Europe. This 
information is envisaged to benefit the entire biobanking and medical research community, as well as to promote 
more harmonized and accessible biobanks.
BBMRI-LPC project 
From 2013-2017,the BBMRI-LPC project (EU FP7 GA no. 313010) assembled 21 LPC studies from 10 countries 
and two EU-wide multinational cohort networks (Table 1) with an objective to promote collaborative transnational 
research on prospective cohorts and analyze the gaps and needs involved. Procedures for bringing together samples 
and data from participating cohorts were developed and three scientific calls for transnational research proposals 
using multiple LPCs organized. For guidance to aspiring users and submission of study proposals, a specific 
BBMRI-LPC access web portal was launched (http://bbmri-lpc.iarc.fr/mica/) providing information about the 
support offered, a cohort catalogue of the available resources and instructions for on-line proposal submission. An 
independent, scientific Review Committee constituting seven BBMRI-LPC members (including cohort 
representatives) was responsible for evaluation of access project proposals based on the specific pre‐defined 
criteria. Proposals were ranked according to their average sum of scores across all categories. In total, 26 research 
proposals were received, of which 11 projects were awarded support (Table 2). Successful applicants received a 
template letter for approaching the cohorts. The BBMRI-LPC access team facilitated the initial contact and 
provided the users with advice on the subsequent steps of the access process. The costs of accessing data and 
samples of the selected cohorts as well as generation of specific types of omics data were funded by the BBMRI-
LPC grant, whereas the downstream analyses had to be covered by other funds of the applicants. The access 
process in the individual projects was closely monitored by the BBMRI-LPC access team. 
In parallel, an interview study was conducted to understand the barriers and facilitators for sample and data sharing 
through the experiences in BBMRI-LPC. In the interviews, experiences and perspectives of individuals involved 
in BBMRI-LPC as well as other professionals or observers in the field were explored. The aim of the interviews 
was to capture trends and strategies for sample and data sharing, as well as to collect feedback from ‘the BBMRI-
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LPC customers’, including the research project applicants and the biobank personnel. The results of the interview 
study will be published separately (M. Murtagh et al). 
Trends and needs in the current access procedures
Any researcher accessing samples or data in a cohort or biobank typically needs to complete three general steps of 
the access process: (1) requesting the access, (2) obtaining the necessary study approvals, and (3) executing the 
access. Below, we describe the current bottlenecks for each of these steps as revealed by close follow-up of 
transnational research projects in the BBMRI-LPC project. 
1. Requesting the access 
1.1. Cataloguing of samples and data 
Evaluating which individual cohorts are suitable to answer a specific research question is rarely 
straightforward, as most cohorts do not provide detailed information on their research resources in a 
harmonized fashion. To facilitate this process for the BBMRI-LPC-supported access research projects, a 
specific access web portal (http://bbmri-lpc.iarc.fr/mica/) was launched where the most relevant information 
on research resources was made easily available in a searchable form. In addition, data in the BBMRI-LPC 
cohort catalogue, a sub-catalogue of the BBMRI-ERIC catalogue of European biobanks [12], was updated 
by inviting 21 participating cohorts to take part in a harmonized exposure and clinical endpoint data 
inventory (http://www.bbmri-lpc-biobanks.eu/). Information on epidemiological exposure data (i.e. any 
factor, which may be associated with an outcome of interest,) was received for 13 cohorts, whereas eight 
cohorts were unable to provide all relevant information mostly due to insufficient financial resources to 
support this activity. Information on clinical endpoints (i.e. primary outcomes, such as diseases or other 
measurable events, measured in a clinical trial) were received for 9 cohorts. For another 12 cohorts, the 
endpoint data were not available at the time of request.
1.2. Centralized support
For researchers formerly unfamiliar with European cohorts, information provided in the cohort catalogue 
itself was in many occasions not sufficient to allow preparation of competitive research proposals. 
Supplementary support by the BBMRI-LPC access team was often required to guide investigators in 
defining the requirements of samples and data for their research project, the specific structure and set-up of 
individual cohorts, as well as how to approach the cohorts. 
1.3. Identification of a correct contact person for the access correspondence 
In some cases, identification of the correct contact person for access correspondence at the cohort took a 
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surprisingly long time. This caused unnecessary delay in initiating the actual access procedures. It is worth 
noting that while the principal investigator of the original cohort study is basically the ideal contact person 
for all scientific matters regarding the cohort, they are generally not the most suitable point of contact for 
assisting with the various administrative and technical practicalities related to access. 
2. Obtaining the necessary study approvals
2.1. Heterogeneous access governance
Some contemporary European cohorts have adopted a service-oriented access governance structure with 
minor scientific involvement required in the downstream research. Such cohorts tend to have strong research 
support to handle the relevant study administrative tasks. Other cohorts, most of which can be considered 
more mature, often require the research to be conducted in close collaboration with a local scientist, who 
would also be in charge of handling many of the local study administrative duties. Whilst the role of a local 
scientist is beneficial in ensuring that the idiosyncrasies of individual cohorts are appropriately 
accommodated in the study setup and conduct, this approach is often rate-limiting as the local scientist may 
have limited time to handle such tasks. Regardless of governance structure, individual cohorts each have 
their own procedures and rules for organizing access to their samples and data, requiring individual users 
who seek access to multiple cohorts to comply with multiple, and  often strongly divergent, access 
procedures. The scope and validity of informed consent from the research participants is often subject to 
evaluation and may limit the secondary uses and data sharing, even if the actual access procedures were 
smooth. The new EU General Data Protection Regulation (GDPR) became effective on May 25, 2018, and 
imposes reassessment of the validity of existing informed consents, if they are used as a lawful basis for 
research.
2.2. Time-consuming local approval procedures
One of the most time-consuming tasks in the access process is obtaining the necessary local scientific and 
ethical approvals. Most cohorts have a local scientific access committee or an equivalent decision body for 
evaluating new access requests. In many cases information about these cohort-specific committees and their 
requirements only became known following the initial access request. As meetings of the local committees 
are typically organized at monthly or bi-monthly intervals, gaining approvals from each of the multiple 
cohorts caused inevitable and varying delays. On some occasions, applicants were also asked to modify their 
proposal or to provide complementary information, which led to additional round(s) of committee review(s) 
before the final decision was made.
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Whilst some selected cohorts have provided overarching ethical approval for future use of their data and 
samples, most require local or national ethics committees (or similar body) to approve any proposed 
research wherein the cohort’s data and/or samples would be accessed. Some national laws also require  a 
review from the data protection authorities. The local ethics committees meet at regular intervals, but rarely 
in conjunction with the local access committees, which tends to generate an additional delay in the approval 
process. In the cohorts with a very streamlined process, the time taken by the local access and ethics 
committees to grant approval was approximately three to four months, while in the worst case the approval 
process took more than a year.
3. Executing the access 
3.1. Material Transfer Agreement (MTA) negotiations
Following approvals from the local access and ethics committees, establishing the necessary MTAs that 
govern use of the cohort data and samples proved to be a complicated administrative effort, typically taking 
many months up to one year to complete. Initially, BBMRI-LPC developed a uniform MTA template that 
was offered as an option to be used by the supported research projects. Despite this effort, the MTA 
negotiations remained restrictively cumbersome. As there are few important differences in laws or 
regulations at national level which should complicate the transfer of samples or data within the EU, the 
problem seemed rather to lie at the institutional level, as most cohorts expressed a strong preference for 
using their own specific MTAs. Transfers of personal data to non-EU or non-Euroepan Economic Area 
(EEA) countries complicate agreements even further due to the EU data protection regime that requires 
adequate safeguards to be fulfilled by the recipient. 
3.2. Delays in organizing and shipping of study samples
Whilst the cohorts generally have well-organized routines for retrieving, preparing and shipping samples, in 
some instances 3 to 12 months’ delay occurred in retrieving the relevant samples and preparing them for 
transfer. The extended sample retrieval times were interpreted to be largely dependent on the availability of 
personnel as well as on the extent of automatic sample manipulation implemented in each of the respective 
cohorts.  
3.3. Data harmonization
In contrast with sample access, organizing and transferring cohort data was relatively straightforward and 
further facilitated by the cohort catalogues. Here, however, a more important bottleneck turned out to be the 
downstream data harmonization. While this activity was not supported under the present BBMRI-LPC 
project, it needs to be commented on here as an important hurdle in multinational cohort science. 
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Smoother access solutions for the cohort-based research projects
Below, we provide a set of recommendations for addressing the bottlenecks identified in collaborative cohort-
based transnational research. The identified challenges and subsequent recommendations are summarized in 
Table 3. 
Importance of cataloguing the cohort resources
The importance of a searchable database with detailed, standardized information on the available cohort samples 
and data is evident. Further, to maintain such a catalogue up-to-date as well as to allow enriching the catalogue 
through generation of new data, sufficient personnel resources along with appropriate IT systems for (semi-) 
automated updates of the individual cohort information are necessary.  In the long term, great progress would be 
made by developing an extended version of the cohort catalogue that supports more detailed search requests and 
allows direct linkage of specific disease cases with  information on the availability of relevant samples and data. 
Enhanced access support services 
There is a clear need for a more efficient support model to better assist European scientists in navigating through 
the sample access procedures. To enhance support for access services at the cohort-level, establishing a 
professional access manager would be a great advantage. A dedicated scientific administrator serving locally as a 
centralized contact point for all access correspondence and providing guidance to researchers with the pertinent 
approval procedures and necessary contracts would not only promote scientific collaboration and 
communication, but also bring greater visibility for a respective cohort or biobank. Smooth access procedures 
require appropriate resourcing. 
Efforts to harmonize access governance structures and approval processes 
In the cohorts, the ethical, legal, administrative and logistic decisions are typically segmented across specific 
committees. On many occasions, however, information on these decision bodies and their requirements is not 
sufficiently clear or publicly available. In addition to publishing the cohort-specific requirements, provision of a 
pre-agreed, uniform proposal template for new access requests would greatly streamline the overall approval 
process of projects involving multiple cohorts.
Despite the time taken by assessment of the local access committees, they are still considered as an inevitable 
step in the approval process. Whilst it would be appealing, for the sake of efficiency, to replace the local access 
committees with one single national body dealing with all transnational cohort-based research, clearly only a few 
                                     
10
cohorts would be willing (or even allowed) to relinquish their governance framework in favor of a centralized 
protocol. Such a body would also require major trust from its constituents to have sufficient knowledge of the 
individual cohorts. In the short term, it is therefore crucial that local access committees have a strong 
administrative organization with clear and streamlined routines to work as efficiently and transparently as 
possible. 
In contrast, as the ethical principles, laws and data security regulations within European countries are relatively 
uniform, having a common independent ethics review board at the European level (such as the ‘BBMRI-ERIC 
Ethics Check’ available at http://www.bbmri-eric.eu/BBMRI-ERIC/ethics-check/), for cohort-based research 
projects could considerably enhance the approval processes, although this would require extensive ‘buy-in’ from 
individual cohorts and governing institutes to be useful. For now, we strongly support one national ethics review 
per country for the consortium-based research projects.  
Standardized MTAs
The ethical and legal framework of European institutes has tightened over the last decade with important 
repercussions for establishing the agreements that govern national and transnational transfer of research material. 
In practical terms, this means that many institutions have developed increasingly complex MTAs that typically 
require case-by-case negotiations involving two institutions (often from different countries) to agree on 
complicated legalese prior to any new sample or data transfer. As much as the scientists in nationally and 
internationally funded research are nowadays held to time-limited deliverables and milestones, it is crucial that 
the legal departments involved in negotiating the necessary MTAs provide timely support. We emphasize the 
importance of pre-determined timeframes, as the obscurity of the schedule may cause unnecessary friction 
between the parties involved. By agreeing the timeframe beforehand, it is possible to avoid juxtaposition 
between the actors and ensure a timely local dialogue between the scientists and the administrators, improving 
transparency and accountability from both sides.
Many consortium projects  have put a lot of effort into developing standardized MTA templates [7]. However, 
without including the legal departments in the development phase to have the majority of institutes agreeing on 
such a template, practical implementation thereof is not realistic. Establishing a truly uniform MTA template (or 
at least a collection of standardized building blocks) has the potential to revolutionize the rate by which transfer 
of data and samples can occur in Europe, hence substantially accelerating biomedical discoveries. This is, 
however, a challenging task that requires close collaboration and mutual agreement of each cohort-associated 
institution. Failing this, applicants in consortium-based research projects will continually be obliged to establish 
a number of different MTAs. In any given research project requiring transfer of data and/or samples, we strongly 
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recommend initiating the MTA processes as early as possible, ideally before or as soon as all necessary study 
approvals are in place. 
Investments into sample management and data harmonization
Sufficient and project-independent core funding is necessary to efficiently fulfill access claims and swiftly 
process the sample requests in the individual cohorts. Whilst for some cohorts a certain gain in efficiency might 
be achievable through organizational changes, substantial reduction of sample preparation time would typically 
require increasing the personnel resources involved in sample retrieval and manipulation and/or introducing 
automation, which would again require additional investments in machinery and robotic sample handling.
In terms of data harmonization, it can often take several months for a skilled computer technician to harmonize a 
complex study database. To avoid having each consortium re-harmonizing the same cohorts’ data for each new 
project, we recommend individual cohorts to assign resources allowing one-off harmonization of common study 
variables required in any consortium-based research project [13,14]. As an example of such an effort, in 2013 the 
US National Cancer Institute supported a comprehensive harmonization effort of a large number of commonly 
used study variables for cohorts participating in the Diabetes and Cancer Initiative (n=28). The code book for 
this harmonization will be made available for other investigators seeking to harmonize data from these cohorts. 
Also, the previously initiated large collaborative FinnGen project (https://www.finngen.fi/en) employs clinical 
expert groups to harmonize endpoint data acquired from the national health registries. Adopting this kind of 
principle would provide one of the most cost-efficient improvements in cohort-based research. As the data 
evolves over time, smart and appropriate IT-solutions are necessary for keeping the information up-to-date and 
documenting the data provenance. Also, innovative ways of sharing data are needed. When samples become data 
via laboratory analyses, it may be feasible to “bring analysis to the data instead of bringing the data to the 
analysis” [15], rather than go through all the steps described above. It should be noted, however, that by GDPR, 
having access to data is equal to data transfer, albeit the data download would have been made technically 
impossible.
Conclusions
Sharing samples and data from different study sources is crucial in attaining new biomedical breakthroughs. 
Divergent access governance structures, complex legal and ethical frameworks and heterogeneous cohort access 
procedures currently constitute substantial obstacles for sample and data transfer in Europe. In addition, lack of 
resources in the publicly funded cohorts is an issue. Public-private partnership (PPP) in large projects, such as 
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FinnGen (https://www.finngen.fi/en), a collaborative research project of nine Finnish biobanks and seven 
pharma companies, is an example how to overcome the funding issues that are often related to the large projects, 
particularly in small countries. On the other hand, PPP naturally creates other layers of complexity which need to 
be dealt with. While the GDPR (EU 2016/679) will harmonize EU practices on personal data protection at the 
meta-level, a lot of decision power, particularly on scientific projects, has been left for the member countries. 
GDPR also sets out rigorous provisions for data processing, administration and privacy impact assessments. The 
validity of old consent may be at stake, if used as a lawful basis for data processing. This probably will not ease 
the challenges described above, but rather re-boot the field in many ways that make it necessary for the scientists 
and ELSI (ethical, legal and social implications) experts to map the situation all over again. Streamlining of 
access provision processes has the potential to greatly enhance use of the unique and invaluable cohort research 
resources and to maximize their impact on high-quality health science. This is a mandatory route, as it is the only 
way to provide health care benefits and life style improvements to the public at large, justifying the efforts of the 
biobank participants. All in all, if the data and samples are used for the original purpose for which they were 
collected, as well as in accord with the informed consent for their use, we see that all unnecessary restrictions 
and artificial boundaries should be curtailed in the interest of public good. 
Funding: This work was supported by the European Commission Seventh Framework Programme [grant no. 
313010].
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Table 1. List of the European LPCs participating in the BBMRI-LPC project.
Cohort name Study design Country Target 
number of 
participants
Website
Cohort of Norway (CONOR) Cohort study NO 200,000 https://www.fhi.no/studier/cohort
-of-norway/ 
Constances Cohort study FR 200,000 http://www.constances.fr/ 
Danish National Birth Cohort (DNBC) Cohort study DK 100,000 http://www.nationalbiobank.dk/ 
Estonian Genome Project (EGP) Cohort study, Other EE 51,535 https://www.geenivaramu.ee/en 
European Prospective Investigation into 
Cancer and Nutrition (EPIC network)
Cohort study EU-wide 521,468 http://epic.iarc.fr/ 
Epidemiology of Health (EpiHealth) Cohort study SE 300,000 https://www.epihealth.se/  
National FINRISK Study Cohort study FI 38,700 http://www.nationalbiobanks.fi/i
ndex.php/studies2/7-finrisk 
Gazel Cohort study FR 20,625 http://www.gazel.inserm.fr 
Genomes for Life. Cohort Study of the 
Genomes of Catalonia (GCAT)
Cohort study ES 50,000 http://www.gcatbiobank.org/ 
Health 2000 Cohort study FI 8,028 https://thl.fi/en/web/thl-
biobank/for-researchers/sample-
collections/health-2000-and-
2011-surveys 
Nord-Trøndelag Health Study (HUNT) Cohort study NO 125,000 https://www.ntnu.edu/hunt
Janus Serum Bank Cohort study NO 318,628 https://www.kreftregisteret.no/en
/Research/Janus-Serum-Bank/ 
Cooperative health research in the region 
of Augsburg (KORA)
Cohort study DE 18,000 https://www.helmholtz-
muenchen.de/kora 
LifeGene Cohort study SE 200,000 https://www.lifegene.se 
Lifelines Cohort Study Cohort study NL 165,000 https://www.lifelines.nl/research
er/biobank-lifelines 
Norwegian Mother and Child Cohort 
Study (MoBA)
Case-control study, 
Cohort study
NO 284,000 https://www.fhi.no/en/studies/mo
ba/ 
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MONICA Risk, Genetics, Archiving and 
Monograph (MORGAM network)
Other EU-wide 128,874 https://thl.fi/morgam/ 
Netherlands Cohort Study (NLCS) Cohort study NL 120,852 https://epi.grants.cancer.gov/Con
sortia/members/nlcs.html 
Rotterdam study Cohort study NL 15,000 http://www.epib.nl/research/ergo
.htm 
TwinGene Cohort study SE 12,600 https://ki.se/en/research/the-
swedish-twin-registry 
United Kingdom Biobank (UK Biobank) Cohort study UK 500,000 https://www.ukbiobank.ac.uk/ 
Total 3,378,310
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Table 2. The access research projects selected in the three BBMRI-LPC scientific calls. A list of scientific 
publications resulting from the access projects is available at http://www.bbmri-lpc.org/access. 
Scientific call Title of the research project (PI, principal investigator)
Country of 
origin
1 Early biomarkers for pancreatic cancer (Prof. Gert-Jan van Ommen) NL
1 Metabolic pathways of kidney cancer (Dr. Mattias Johansson) FR
1 Markers of imminent myocardial infarction (Prof. Johan Sundström) SE
1 Exposure to brominated disinfection by-products and prospective metabolic 
alteration (Dr. Konstantinos Makris)
CY
2 Biomarkers of human papillomavirus (HPV) infection and risk of two 
increasing cancers (Dr. Tim Waterboer)
DE
2 Metabolic Profiling and Colorectal Cancer Risk (Dr. Marc Gunter) UK
2 Exploring the genetics of irritable bowel syndrome (Prof. Mauro D’Amato) ES
2 Biomarkers of ischemic stroke in prospective cohorts (Dr. Christian Gieger) DE
3 Identification of biomarkers for gallbladder cancer risk prediction (Prof. 
Bermejo Lorenzo)
DE
3 The influence of macronutrient dietary patterns on pregnancy (Prof. Janet 
Cade)
UK
3 Unravelling the role of Bile Pigments in Colorectal Cancer (Prof. Karl-Heinz 
Wagner)
AT
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Table 3. The bottlenecks identified and recommendations on measures to improve the transnational access 
provision to European cohorts/biobanks.
1. REQUESTING THE ACCESS
Bottleneck Recommendation(s) Category
Cataloguing of samples and 
data
Local investments for cataloguing the cohort resources in a 
standardized fashion
Up to date maintenance of the catalogue information
Financial resources
Centralized access support A dedicated contact person appointed for access 
correspondence at the cohort (access manager)
Access governance, 
personnel resources
2. GETTING THE ACCESS APPROVED
Bottleneck Recommendation(s) Category
Heterogeneous access 
governance structures
Harmonization of the access policies nationally and 
internationally 
An access research proposal template pre-agreed by the 
cohorts
Access governance
Time-consuming local 
approval processes
Information on the local decision bodies and their 
requirements available
Strong administrative organization of the local decision 
bodies
Access governance
3. EXECUTING THE ACCESS
Bottleneck Recommendation Category
MTA/DTA negotiations Standardized MTA/DTA or a collection of standardized 
building blocks.
Initiation of the MTA/DTA review process early upon 
project approval
Importance of agreeing on the pre-determined time frames
Access governance
Delays in organizing and 
shipping of study samples
Local investments in biobanks’ personnel and sample 
management automation.
Financial resources
Data harmonization A cohort-wise one-off harmonization of common study  
variables
Financial resources
